Ghent University Academic Bibliography

A characterization of the HIV population with limited/exhausted treatment options : a multicenter Belgian study

Rakan Nasreddine, Gilles Darcis, Jean Cyr Yombi, Paul De Munter, Eric Florence, Jens Van Praet (UGent) , Rémy Demeester, Sabine D. Allard, Melanie Schroeder, Ange-Clarisse Dusabineza, et al.

(2024) ACTA CLINICA BELGICA. 79(3). p.153-159

Add to list

Journal Article
A1
open access

Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study

Jozefien De Clercq (UGent) , Marie-Angélique De Scheerder (UGent) , Sophie Vanherrewege (UGent) , Els Caluwe (UGent) , Nathalie Moreels (UGent) , Danny Delooze, Annemieke Dhondt (UGent) , Marc Coppens (UGent) , Stefaan J. Vandecasteele, Sabine D. Allard, et al.

(2024) JOURNAL OF VIRUS ERADICATION. 10(3).

Add to list

Journal Article
A1
open access

Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir

Jozefien De Clercq (UGent) , Marie-Angélique De Scheerder (UGent) , Virginie Mortier (UGent) , Chris Verhofstede (UGent) , Stefaan J. Vandecasteele, Sabine D. Allard, Coca Necsoi, Stephane De Wit, Sarah Gerlo (UGent) and Linos Vandekerckhove (UGent)

(2024) FRONTIERS IN IMMUNOLOGY. 14.

Add to list

Conference Paper
C3
open access

Linking inducible HIV-1 reservoir to rebound after treatment interruption

Laurens Lambrechts, Ytse Noppe (UGent) , Marion Pardons (UGent) , Basiel Cole, Sofie Rutsaert (UGent) , Stéphane De Wit, Guido Vanham, Eric Florence and Linos Vandekerckhove (UGent)

(2023) IAS 2023 Abstract Book. p.77-78

Add to list

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet (UGent) , Linos Vandekerckhove (UGent) , Sabine D. Allard, Rémy Demeester, Peter Messiaen, et al.

(2023) HIV MEDICINE. 24(8). p.914-924

Add to list

Journal Article
A1
open access

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D'Antoni, Christiana Blair, Susan K. Chuck, et al.

(2023) HIV MEDICINE. 24(1). p.27-36

Add to list

Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort

Rakan Nasreddine, Eric Florence, Michel Moutschen, Jean‐Cyr Yombi, Jean‐Christophe Goffard, Inge Derdelinckx, Patrick Lacor, Linos Vandekerckhove (UGent) , Peter Messiaen, Stefaan Vandecasteele, et al.

(2021) JOURNAL OF MEDICAL VIROLOGY. 93(5). p.2971-2978

Add to list

Journal Article
A1
open access

Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, et al.

(2021) INFECTIOUS DISEASES AND THERAPY. 10(2). p.775-788

Add to list

Journal Article
A1
open access

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription

Pieter Pannus, Sofie Rutsaert (UGent) , Stéphane De Wit, Sabine D. Allard, Guido Vanham, Basiel Cole, Coca Nescoi, Joeri Aerts, Ward De Spiegelaere (UGent) , Achilleas Tsoumanis, et al.

(2020) JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 23(2).

Add to list

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

Laura Dickinson, Rohan Gurjar, Wolfgang Stöhr, Stefano Bonora, Andrew Owen, Antonio D’Avolio, Adam Cursley, Jean-Michel Molina, Gerd Fäetkenheuer, Linos Vandekerckhove (UGent) , et al.

(2020) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 75(3). p.628-639

Academic Bibliography

A characterization of the HIV population with limited/exhausted treatment options : a multicenter Belgian study

Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study

Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir

Linking inducible HIV-1 reservoir to rebound after treatment interruption

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort

Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

Contents

Support

Contact